https://www.selleckchem.com/pr....oducts/nazartinib-eg
II BC patients younger than 65 when compared to the scores of those with de novo stage IV BC. Although treatment with or without LRT did not affect physical health, mental health, daily activities, and energy at 3years vs. at diagnosis of BC in de novo stage IV BC patients (p 0.05), these variables were significantly better in stage I-III BC patients (p 0.001). The current MF07-01Q study demonstrates that patient who had LRT has similar physical and mental health outcomes compared to ST only in a cohort of pati
Like
Comment
Share
